Penumbra, Inc.

Valuation Analysis

About the Company

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and ot

Penumbra, Inc. Stock at a Glance

Penumbra, Inc. (PEN) is currently trading at $318.71 with a market capitalization of $12.5B. The trailing P/E ratio stands at 73.61x, with a forward P/E of 50.66x. The 52-week range spans from $221.26 to $362.41; the current price is 12.1% below the yearly high. Year-over-year revenue growth stands at +15.6%. The net profit margin stands at 11.76%.

💰 Dividend

Penumbra, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

14 analysts rate Penumbra, Inc. (PEN) on consensus: Hold. The average price target is $363.36, implying +14.01% from the current price. Analyst price targets range from $326.00 to $374.00.

Penumbra, Inc.: The Investment Case in Detail

Penumbra, Inc. (PEN) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 15.6% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 67.38%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

The Bear Case

A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

With a PEG ratio of 0.74, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 59.5x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

What to Watch Next

• The forward P/E of 50.66x is meaningfully below the trailing 73.61x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (5.6%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Penumbra, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.